Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review

CD22 is a transmembrane sialoglycoprotein and a member of the immunoglobulin superfamily. Its expression is restricted to the B cell lineage and a vast majority of B cell NHLs. CD22 plays a key role in B cell development, survival, and function. Humanized anti-CD22 antibodies were developed to minim...

Full description

Saved in:
Bibliographic Details
Published inZhongguo shi yan xue ye xue za zhi Vol. 14; no. 6; p. 1258
Main Authors Lu, Ping-Ping, Meng, Zhi-Yun, Zhou, Ming-Xiao, Wang, Min-Wei, Dou, Gui-Fang
Format Journal Article
LanguageChinese
Published China 01.12.2006
Subjects
Animals
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Humans
Immunotherapy
Lymphoma, Non-Hodgkin - therapy
Sialic Acid Binding Ig-like Lectin 2 - immunology
Online AccessGet more information

Cover

More Information
Summary:CD22 is a transmembrane sialoglycoprotein and a member of the immunoglobulin superfamily. Its expression is restricted to the B cell lineage and a vast majority of B cell NHLs. CD22 plays a key role in B cell development, survival, and function. Humanized anti-CD22 antibodies were developed to minimize the immunogenicity and to enhance effector interactions during their developments of diagnostic and immunotherapeutic agent. Preclinical test with anti-CD22 antibodies indicates that a single, conjugated or radiolabeled agent has shown preliminary antitumor activity in patients with recurrent and heavily pretreated NHL. Anti-CD22 antibodies were well tolerated, without dose-dependant toxicity. Anti-CD22 antibodies are currently being evaluated in combination with rituximab, and the early results suggest that the combination of the two antibodies are well tolerated and may result in better clinical activity than the single agent alone. Thus, anti-CD22 antibodies are theoretically good candidates alone and in com
ISSN:1009-2137